Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities researchers at Raymond James issued their FY2029 earnings per share estimates for shares of Medexus Pharmaceuticals in a report released on Tuesday, November 19th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $0.89 per share for the year. Raymond James currently has a "Outperform" rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.
Several other equities research analysts also recently weighed in on MDP. Stifel Nicolaus raised their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a "buy" rating in a research report on Thursday, August 22nd. Stifel Canada raised Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a report on Monday, August 12th. Finally, Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a report on Monday, September 30th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of C$5.25.
View Our Latest Stock Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
TSE:MDP opened at C$2.15 on Thursday. The firm has a market cap of C$52.74 million, a P/E ratio of 43.00 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.44 and a fifty-two week high of C$3.16. The firm has a 50-day simple moving average of C$2.48 and a two-hundred day simple moving average of C$2.19.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
